Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study

Chronic prurigo

(2022) Laurent Misery   BRITISH JOURNAL OF DERMATOLOGY

Itch intensity in prurigo nodularis is closely related with dermal interleukin‐31, oncostatin M, IL‐31 receptor alpha, and oncostatin M receptor beta

(2021) Takashi Hashimoto et al.   EXPERIMENTAL DERMATOLOGY

Pruritus as a Distinctive Feature of Type 2 Inflammation

(2021) Simone Garcovich et al.   Vaccines

Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis

(2020) Sonja Ständer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Practical approaches for diagnosis and management of prurigo nodularis: US expert panel consensus

(2020) Sarina Elmariah et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Prevalence of prurigo nodularis in the United States

(2020) Katherine A. Whang et al.   Journal of Allergy and Clinical Immunology-In Practice

Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis

(2020) Kyle A. Williams et al.   Expert Review of Clinical Pharmacology

202 The Oncostatin M receptor beta axis identified in prurigo nodularis

(2019) Z. Mikhak et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

560 KPL-716, anti-Oncostatin M receptor beta antibody, reduced pruritus in atopic dermatitis

(2019) Z. Mikhak et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus

(2019) Jonathan I. Silverberg et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Real-world prevalence of prurigo nodularis and burden of associated diseases

(2019) Amy H. Huang et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Chronic Prurigo of Nodular Type: A Review

(2018) C Zeidler et al.   ACTA DERMATO-VENEREOLOGICA

In vivo affinity and target engagement in skin and blood in a first-time-in-human study of an anti-oncostatin M monoclonal antibody

(2018) Juliet Reid et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IL-31: A new key player in dermatology and beyond

(2018) Işın Sinem Bağci et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Prurigo Activity Score (PAS): validity and reliability of a new instrument to monitor chronic prurigo

(2018) J. Pölking et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need

(2018) M.P. Pereira et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The self-assessed psychological comorbidities of prurigo in European patients: a multicentre study in 13 countries

(2018) E. Brenaut et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial

(2018) Sabine Steinke et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Anxiety, depression and suicide in patients with prurigo nodularis

(2016) K.M. Jørgensen et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The Worst Itch Numeric Rating Scale for patients with moderate to severe plaque psoriasis or psoriatic arthritis

(2014) April N. Naegeli et al.   INTERNATIONAL JOURNAL OF DERMATOLOGY

The 5-D itch scale: a new measure of pruritus

(2009) S. Elman et al.   BRITISH JOURNAL OF DERMATOLOGY

Evaluation of the impact of fibromyalgia on patients' sleep and the content validity of two sleep scales

(2009) Susan Martin et al.   Health and Quality of Life Outcomes